The intranasal method was developed by William Frey II, senior director of HealthPartners Research Foundation’s Alzheimer’s Research Center, and his colleagues.
According to Sanomune, the new method allows medication to bypass the protective blood-brain barrier and enter the brain directly. Dr Frey developed a way to bypass the barrier for neurological conditions using intranasal delivery of deferoximine or SAN-121.
Dr Frey said: “With our non-invasive delivery method, the drug bypasses the blood-brain barrier and is rapidly delivered to the brain while significantly reducing unwanted side effects. Because it is able to reach key areas involved in both Alzheimer’s disease and Parkinson’s disease, we are very optimistic about its potential as a treatment for these disorders.”